A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.

Antibodies (Basel) · 2018 · PMC6698870 · PMID 31544864

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

For example, although the majority (~65%) of clinical ADCs are based on random payload attachment [ 4 ], a clear trend toward site-specifically conjugated ADCs based on engineered cysteine can be noted (currently >10 in the clinic), generally showing an increased therapeutic index [ 5 , 6 ].

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.